These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 24647557)

  • 1. Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK.
    Elsone L; Kitley J; Luppe S; Lythgoe D; Mutch K; Jacob S; Brown R; Moss K; McNeillis B; Goh YY; Leite MI; Robertson N; Palace J; Jacob A
    Mult Scler; 2014 Oct; 20(11):1533-40. PubMed ID: 24647557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder.
    Chen H; Qiu W; Zhang Q; Wang J; Shi Z; Liu J; Lian Z; Feng H; Miao X; Zhou H
    Eur J Neurol; 2017 Jan; 24(1):219-226. PubMed ID: 27783452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies.
    Kitley J; Elsone L; George J; Waters P; Woodhall M; Vincent A; Jacob A; Leite MI; Palace J
    J Neurol Neurosurg Psychiatry; 2013 Aug; 84(8):918-21. PubMed ID: 23467418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.
    Yang Y; Wang CJ; Wang BJ; Zeng ZL; Guo SG
    J Neurol Sci; 2018 Feb; 385():192-197. PubMed ID: 29406904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica.
    Costanzi C; Matiello M; Lucchinetti CF; Weinshenker BG; Pittock SJ; Mandrekar J; Thapa P; McKeon A
    Neurology; 2011 Aug; 77(7):659-66. PubMed ID: 21813788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of rituximab versus oral immunosuppressive therapies in neuromyelitis optica spectrum disorder in a racially diverse cohort of subjects: A single-center retrospective study.
    Dresser L; Chaar WA; Reder AT; Abuaf AF; Cipriani VP; Javed A
    Mult Scler Relat Disord; 2023 Jun; 74():104718. PubMed ID: 37086634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica.
    Jarius S; Aboul-Enein F; Waters P; Kuenz B; Hauser A; Berger T; Lang W; Reindl M; Vincent A; Kristoferitsch W
    Brain; 2008 Nov; 131(Pt 11):3072-80. PubMed ID: 18945724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Ma J; Yu H; Wang H; Zhang X; Feng K
    J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.
    Carnero Contentti E; Correale J
    J Neuroinflammation; 2021 Sep; 18(1):208. PubMed ID: 34530847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica.
    Kageyama T; Komori M; Miyamoto K; Ozaki A; Suenaga T; Takahashi R; Kusunoki S; Matsumoto S; Kondo T
    J Neurol; 2013 Feb; 260(2):627-34. PubMed ID: 23076828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial.
    Nikoo Z; Badihian S; Shaygannejad V; Asgari N; Ashtari F
    J Neurol; 2017 Sep; 264(9):2003-2009. PubMed ID: 28831548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis.
    Espiritu AI; Pasco PMD
    Mult Scler Relat Disord; 2019 Aug; 33():22-32. PubMed ID: 31136907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: A prospective cohort study.
    Xu Y; Wang Q; Ren HT; Qiao L; Zhang Y; Fei YY; Zhao Y; Cui LY
    J Neurol Sci; 2016 Nov; 370():224-228. PubMed ID: 27772764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica.
    Qiu W; Kermode AG; Li R; Dai Y; Wang Y; Wang J; Zhong X; Li C; Lu Z; Hu X
    J Clin Neurosci; 2015 Jul; 22(7):1178-82. PubMed ID: 26006157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial effects of intravenous immunoglobulin as an add-on therapy to azathioprine for NMO-IgG-seropositive neuromyelitis optica spectrum disorders.
    Lim YM; Kim H; Lee EJ; Kim HW; Kim HJ; Kim KK
    Mult Scler Relat Disord; 2020 Jul; 42():102109. PubMed ID: 32387973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of efficacy and tolerability of first-line therapies in NMOSD.
    Poupart J; Giovannelli J; Deschamps R; Audoin B; Ciron J; Maillart E; Papeix C; Collongues N; Bourre B; Cohen M; Wiertlewski S; Outteryck O; Laplaud D; Vukusic S; Marignier R; Zephir H;
    Neurology; 2020 Apr; 94(15):e1645-e1656. PubMed ID: 32170036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response.
    Stellmann JP; Krumbholz M; Friede T; Gahlen A; Borisow N; Fischer K; Hellwig K; Pache F; Ruprecht K; Havla J; Kümpfel T; Aktas O; Hartung HP; Ringelstein M; Geis C; Kleinschnitz C; Berthele A; Hemmer B; Angstwurm K; Young KL; Schuster S; Stangel M; Lauda F; Tumani H; Mayer C; Zeltner L; Ziemann U; Linker RA; Schwab M; Marziniak M; Then Bergh F; Hofstadt-van Oy U; Neuhaus O; Zettl U; Faiss J; Wildemann B; Paul F; Jarius S; Trebst C; Kleiter I;
    J Neurol Neurosurg Psychiatry; 2017 Aug; 88(8):639-647. PubMed ID: 28572277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder.
    Ringelstein M; Ayzenberg I; Harmel J; Lauenstein AS; Lensch E; Stögbauer F; Hellwig K; Ellrichmann G; Stettner M; Chan A; Hartung HP; Kieseier B; Gold R; Aktas O; Kleiter I
    JAMA Neurol; 2015 Jul; 72(7):756-63. PubMed ID: 25985228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between Azathioprine metabolites and therapeutic efficacy in Chinese patients with neuromyelitis optica spectrum disorders.
    Li X; Mei S; Gong X; Zhou H; Yang L; Zhou A; Liu Y; Li X; Zhao Z; Zhang X
    BMC Neurol; 2017 Jul; 17(1):130. PubMed ID: 28679367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial.
    Zhang C; Zhang M; Qiu W; Ma H; Zhang X; Zhu Z; Yang CS; Jia D; Zhang TX; Yuan M; Feng Y; Yang L; Lu W; Yu C; Bennett JL; Shi FD;
    Lancet Neurol; 2020 May; 19(5):391-401. PubMed ID: 32333897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.